Drapkin Kimberlee C
SEC-identified person · CIK 1340881 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Lenz Therapeutics, Inc. LENZ | Director | filed 2023–2026 |
| Eliem Therapeutics, Inc. ELYM | Director | filed 2025–2026 |
| Acumen Pharmaceuticals, Inc. ABOS | Director | filed 2022–2026 |
| Yumanity Therapeutics, INC. YMTX | Director | filed 2019–2025 |
| Jounce Therapeutics, Inc. JNCE | President, CFO and Treasurer | filed 2017–2023 |
| Epix Pharmaceuticals, Inc. EPIX | Chief Financial Officer | filed 2006–2009 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.